<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029845</url>
  </required_header>
  <id_info>
    <org_study_id>00084875</org_study_id>
    <nct_id>NCT03029845</nct_id>
  </id_info>
  <brief_title>Propranolol for Treating Fibromyalgia Pain</brief_title>
  <official_title>Propranolol for Treating Fibromyalgia Pain: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study to evaluate the feasibility of using low dose propranolol for people&#xD;
      with fibromyalgia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to collect pilot feasibility study data for the use of low&#xD;
      dose propranolol for helping treat fibromyalgia. The investigators plan to compare 20mg twice&#xD;
      a day dosage of propranolol and 10mg twice a day dosage of propranolol to placebo. The design&#xD;
      is a 3 arm, double blind randomized control trial. The investigators will also test ECG and&#xD;
      respiratory assessment as a part of the safety screening and the feasible assessment of&#xD;
      respiratory sinus arrhythmia.&#xD;
&#xD;
      Propranolol is not indicated to treat pain. However, the previous studies showed that low&#xD;
      dose propranolol can re-regulate the adrenergic dysfunction and reduce pain in people with&#xD;
      chronic musculoskeletal pain. However, the investigators are not aiming to develop a new&#xD;
      indication of the drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The funding ended.&#xD;
  </why_stopped>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in self-reported measures of clinical pain using Fibromyalgia Impact Questionnaire - Revised (FIQ-R)</measure>
    <time_frame>Pre (one week before start taking propranolol or placebo) and Post (immediately following the 14-day trial)</time_frame>
    <description>Changes in clinical pain will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported measures of Fibromyalgia symptoms using Promis Fatigue</measure>
    <time_frame>Pre (one week before start taking propranolol or placebo) and Post (immediately following the 14-day trial)</time_frame>
    <description>Changes in fibromyalgia-related symptoms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Fibromyalgia Pain</condition>
  <arm_group>
    <arm_group_label>propranolol 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg propranolol twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propranolol 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg propranolol twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol 1</intervention_name>
    <description>Participants will take 20 mg propranolol twice a day for 2 weeks</description>
    <arm_group_label>propranolol 1</arm_group_label>
    <other_name>20 mg propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol 2</intervention_name>
    <description>Participants will take 10 mg propranolol twice a day for 2 weeks</description>
    <arm_group_label>propranolol 2</arm_group_label>
    <other_name>10 mg propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take placebo twice a day for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females with fibromyalgia (both meeting 1990 American College of Rheumatology (ACR)&#xD;
             FMS criteria and 2010 ACR FMS criteria) age 18-65 with at least 1 year of symptoms and&#xD;
             sedentary (exercising less than 120 min per week).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General Health Criteria:&#xD;
&#xD;
               -  Uncontrolled/unstable illnesses (physician diagnosed, self-report)&#xD;
&#xD;
               -  Pregnancy or planning to be pregnant in the next year&#xD;
&#xD;
               -  Having Asthma requiring medication treatment including inhaler&#xD;
&#xD;
               -  Type I diabetes or Type II diabetes requiring medical therapy that can lead to&#xD;
                  hypoglycemia&#xD;
&#xD;
               -  Having acute pain or neuropathic pain&#xD;
&#xD;
               -  Participation in exercise or psychological treatment studies in the past 2 years&#xD;
&#xD;
               -  Having known serious psychopathology: Psychosis, history of inpatient psychiatric&#xD;
                  admission in the past year, active suicidal intent, history of self-injurious&#xD;
                  behaviors in the past year, history of recreational IV drug use, substance abuse&#xD;
                  history in the past year)&#xD;
&#xD;
          -  Cardiovascular Criteria:&#xD;
&#xD;
               -  Having known cardiovascular diseases (self-report, physician diagnosed)&#xD;
&#xD;
               -  Pacemaker&#xD;
&#xD;
               -  Bradycardia (resting heartrate of less than 55 bpm)&#xD;
&#xD;
               -  Resting diastolic BP &lt; 55 mmHG or systolic BP&lt;100 mmHG&#xD;
&#xD;
               -  ECG showing prolonged PR interval &gt; .2 sec&#xD;
&#xD;
               -  ECG showing irregular PR interval&#xD;
&#xD;
               -  ECG showing incongruence between P wave and QRS&#xD;
&#xD;
          -  Medication Criteria&#xD;
&#xD;
               -  Allergy or intolerance of beta blockers&#xD;
&#xD;
               -  Current use of the following drugs:&#xD;
&#xD;
                    -  Antihypertensive drugs&#xD;
&#xD;
                    -  Neuroleptics&#xD;
&#xD;
                    -  Monoamine oxidase inhibitors&#xD;
&#xD;
                    -  Tizanidine&#xD;
&#xD;
                    -  Amphetamine-based medications&#xD;
&#xD;
                    -  Bupropion&#xD;
&#xD;
                    -  Mirtazapine&#xD;
&#xD;
                    -  Tricyclics: daily dose greater than 75mg amitriptyline or equivalent&#xD;
&#xD;
                    -  Benzodiazepine: daily dose greater than 5mg diazepam or equivalent&#xD;
&#xD;
                    -  Asthmatic medicine, including inhaler&#xD;
&#xD;
               -  Participants may be included after minimum of 4 weeks of physician prescribed&#xD;
                  termination of these drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akiko Okifuji, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Akiko Okifuji</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

